Xilio Therapeutics, Inc. - XLO
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Feb 17, 2026 | SCHEDULE 13G/A | StemPoint Capital LP | 8.4% | 6,030,028 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | StemPoint Capital Management GP LLC | 8.4% | 6,030,028 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Michelle Ross | 8.4% | 6,030,028 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Bain Capital Life Sciences Fund II, L.P. | 1.3% | 992,111 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BCIP Life Sciences Associates, LP | 0.2% | 120,833 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BCLS II Equity Opportunities, LP | 8.5% | 6,259,742 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BCLS II Investco, LP | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Frazier Life Sciences Public Fund, L.P. | 6.7% | 4,676,472 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLSP, L.P. | 6.7% | 4,676,472 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLSP, L.L.C. | 6.7% | 4,676,472 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Frazier Life Sciences X, L.P. | 0.2% | 149,060 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLS X, L.P. | 0.2% | 149,060 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLS X, L.L.C. | 0.2% | 149,060 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Frazier Life Sciences XI, L.P. | 0.6% | 396,902 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLS XI, L.P. | 0.6% | 396,902 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLS XI, L.L.C. | 0.6% | 396,902 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Frazier Life Sciences XII, L.P. | 1.0% | 692,657 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLS XII, L.P. | 1.0% | 692,657 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLS XII, L.L.C. | 1.0% | 692,657 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | James N. Topper | 0.2% | 149,060 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Patrick J. Heron | 0.2% | 149,060 | View |
| Feb 12, 2026 | SCHEDULE 13G/A | GILEAD SCIENCES, INC. | 19.9% | 14,517,678 | View |
| Dec 11, 2025 | SCHEDULE 13G | Coastlands Capital LP | 9.99% | 5,346,069 | View |
| Dec 11, 2025 | SCHEDULE 13G | Coastlands Capital Partners LP | 9.99% | 5,346,069 | View |
| Dec 11, 2025 | SCHEDULE 13G | Coastlands Capital GP LLC | 9.99% | 5,346,069 | View |
| Dec 11, 2025 | SCHEDULE 13G | Coastlands Capital LLC | 9.99% | 5,346,069 | View |
| Dec 11, 2025 | SCHEDULE 13G | Matthew D. Perry | 9.99% | 5,346,069 | View |
| Nov 14, 2025 | SCHEDULE 13G | StemPoint Capital LP | 7.2% | 4,000,000 | View |
| Nov 14, 2025 | SCHEDULE 13G | StemPoint Capital Management GP LLC | 7.2% | 4,000,000 | View |
| Nov 14, 2025 | SCHEDULE 13G | Michelle Ross | 7.2% | 4,000,000 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Point72 Asset Management, L.P. | 9.9% | 8,000,000 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Point72 Capital Advisors, Inc. | 9.9% | 8,000,000 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Steven A. Cohen | 9.9% | 8,000,000 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.